Fractyl Health Q2 net loss narrows on lower expenses
GUTS•Cash runway guidance reiterated
Fractyl reiterated guidance that its cash runway extends into early 2027, beyond the anticipated pivotal data readout.
Key details and analyst coverage
| Metric | Actual |
|---|---|
| Q2 net loss | $25.50 mln |
| Q2 adjusted EBITDA | -$16.30 mln |
The current average analyst rating on the shares is "buy," with 6 "strong buy" or "buy" ratings, 1 "hold" rating and no "sell" or "strong sell" ratings.
The average consensus recommendation for the biotechnology & medical research peer group is "buy."
Wall Street's median 12-month price target for Fractyl Health, Inc. is $5.10, about 629% above its August 7 closing price of $0.70.
Lower R&D spending and safety update
The company said second-quarter research and development expenses fell mainly due to reduced spending on its Revita and Rejuva programs.
Fractyl also said no device- or procedure-related serious adverse events occurred through one year in Revita studies.
Q2 loss narrows on lower operating expenses
Fractyl Health's second-quarter net loss narrowed from a year earlier on lower operating expenses.
The US metabolic therapeutics firm said its Q2 adjusted EBITDA loss also narrowed year over year, reflecting reduced operating expenses.
